Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Novartis
Citi
Cantor Fitzgerald
Moodys
Teva
Fuji
Argus Health
Healthtrust
Farmers Insurance

Generated: February 22, 2018

DrugPatentWatch Database Preview

Valeant Pharms Intl Company Profile

« Back to Dashboard

What is the competitive landscape for VALEANT PHARMS INTL, and what generic alternatives to VALEANT PHARMS INTL drugs are available?

VALEANT PHARMS INTL has five approved drugs.

There are twenty-four US patents protecting VALEANT PHARMS INTL drugs.

There are one hundred and six patent family members on VALEANT PHARMS INTL drugs in thirty-one countries and one supplementary protection certificate in one country.

Summary for Valeant Pharms Intl
International Patents:106
US Patents:24
Tradenames:4
Ingredients:3
NDAs:5

Drugs and US Patents for Valeant Pharms Intl

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms Intl APRISO mesalamine CAPSULE, EXTENDED RELEASE;ORAL 022301-001 Oct 31, 2008 RX Yes Yes 8,337,886 ➤ Try a Free Trial Y ➤ Try a Free Trial
Valeant Pharms Intl UCERIS budesonide AEROSOL, FOAM;RECTAL 205613-001 Oct 7, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Valeant Pharms Intl UCERIS budesonide TABLET, EXTENDED RELEASE;ORAL 203634-001 Jan 14, 2013 RX Yes Yes 9,532,954 ➤ Try a Free Trial Y ➤ Try a Free Trial
Valeant Pharms Intl GIAZO balsalazide disodium TABLET;ORAL 022205-001 Feb 3, 2012 AB RX Yes Yes 7,452,872 ➤ Try a Free Trial ➤ Try a Free Trial
Valeant Pharms Intl UCERIS budesonide TABLET, EXTENDED RELEASE;ORAL 203634-001 Jan 14, 2013 RX Yes Yes 8,895,064 ➤ Try a Free Trial Y ➤ Try a Free Trial
Valeant Pharms Intl UCERIS budesonide TABLET, EXTENDED RELEASE;ORAL 203634-001 Jan 14, 2013 RX Yes Yes 9,132,093 ➤ Try a Free Trial Y ➤ Try a Free Trial
Valeant Pharms Intl GIAZO balsalazide disodium TABLET;ORAL 022205-001 Feb 3, 2012 AB RX Yes Yes 8,497,256 ➤ Try a Free Trial ➤ Try a Free Trial
Valeant Pharms Intl GIAZO balsalazide disodium TABLET;ORAL 022205-001 Feb 3, 2012 AB RX Yes Yes 6,197,341 ➤ Try a Free Trial Y ➤ Try a Free Trial
Valeant Pharms Intl GIAZO balsalazide disodium TABLET;ORAL 022205-001 Feb 3, 2012 AB RX Yes Yes 9,192,616 ➤ Try a Free Trial ➤ Try a Free Trial
Valeant Pharms Intl APRISO mesalamine CAPSULE, EXTENDED RELEASE;ORAL 022301-001 Oct 31, 2008 RX Yes Yes 8,956,647 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Valeant Pharms Intl

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms Intl UCERIS budesonide AEROSOL, FOAM;RECTAL 205613-001 Oct 7, 2014 5,914,122 ➤ Try a Free Trial
Valeant Pharms Intl COLAZAL balsalazide disodium CAPSULE;ORAL 020610-001 Jul 18, 2000 4,412,992*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VALEANT PHARMS INTL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 1.1 g ➤ Subscribe 11/5/2013
➤ Subscribe Extended-release Tablets 9 mg ➤ Subscribe 3/11/2013
➤ Subscribe Extended-release Capsules 0.375 g ➤ Subscribe 4/3/2012
Premature patent expirations for VALEANT PHARMS INTL

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Try a Free Trial ➤ Try a Free Trial

Non-Orange Book US Patents for Valeant Pharms Intl

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,277,412 Pellet-type formulation intended for treating the intestinal tract ➤ Try a Free Trial
8,029,823 Controlled release and taste masking oral pharmaceutical composition ➤ Try a Free Trial
9,592,203 Controlled release and taste masking oral pharmaceutical composition ➤ Try a Free Trial
9,737,489 Controlled release and taste masking oral pharmaceutical composition ➤ Try a Free Trial
7,547,451 Pellet formulation for the treatment of the intestinal tract ➤ Try a Free Trial
7,410,652 Controlled release and taste masking oral pharmaceutical composition ➤ Try a Free Trial
8,921,344 Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Valeant Pharms Intl Drugs

Supplementary Protection Certificates for Valeant Pharms Intl Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/033 United Kingdom ➤ Try a Free Trial PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Covington
Moodys
AstraZeneca
Boehringer Ingelheim
Accenture
Medtronic
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot